Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (401-410 of 566) with videos related to

Pageof 57
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
Leukemia|February 24, 2021
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patientsAlissa Visram, Iuliana Vaxman, Abdullah S Al Saleh, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
American Journal of Hematology|June 11, 2021
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trialsM Hasib Sidiqi, Abdullah S Al Saleh, Shaji K Kumar, et al.
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Annals of Medicine|March 9, 2017
Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognitionEli Muchtar, Angela Dispenzieri, Martha Q Lacy, et al.
Blood Cancer Journal|December 18, 2019
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myelomaJames Smadbeck, Jess F Peterson, Kathryn E Pearce, et al.
Mayo Clinic Proceedings|October 8, 2016
Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and OutcomeEli Muchtar, Daniele Derudas, Michelle Mauermann, et al.
Pageof 57

Showing results (401-410 of 566) with videos related to

Sort By:
Pageof 57
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
Leukemia|February 24, 2021
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patientsAlissa Visram, Iuliana Vaxman, Abdullah S Al Saleh, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
American Journal of Hematology|June 11, 2021
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trialsM Hasib Sidiqi, Abdullah S Al Saleh, Shaji K Kumar, et al.
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Annals of Medicine|March 9, 2017
Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognitionEli Muchtar, Angela Dispenzieri, Martha Q Lacy, et al.
Blood Cancer Journal|December 18, 2019
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myelomaJames Smadbeck, Jess F Peterson, Kathryn E Pearce, et al.
Mayo Clinic Proceedings|October 8, 2016
Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and OutcomeEli Muchtar, Daniele Derudas, Michelle Mauermann, et al.
Pageof 57